ID
43834
Beskrivning
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Demography Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast
Länk
https://clinicaltrials.gov/ct2/show/NCT00078572
Nyckelord
Versioner (2)
- 2017-05-18 2017-05-18 -
- 2021-09-20 2021-09-20 -
Uppladdad den
20 september 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
Beskrivning
Demography for Females
Alias
- UMLS CUI-1
- C0011298
- UMLS CUI-2
- C0086287
Beskrivning
Childbearing potential
Datatyp
text
Alias
- UMLS CUI [1]
- C3831118
Beskrivning
contraception
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C0700589
- UMLS CUI [1,2]
- C0420837
Beskrivning
Contraception
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0700589
- UMLS CUI [1,2]
- C0420837
Beskrivning
Pregnancy test result
Datatyp
text
Alias
- UMLS CUI [1]
- C0032976
Similar models
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572
C0086287 (UMLS CUI-2)
C0420837 (UMLS CUI [1,2])
C0420837 (UMLS CUI [1,2])